Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 1,148,479 | 987,239 | 971,858 | 1,378,104 | 1,467,491 | 5,953,171 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 1,148,479 | 987,239 | 971,858 | 1,378,104 | 1,467,491 | 5,953,171 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | 5,953,171 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 1,148,479 | 987,239 | 971,858 | 1,378,104 | 1,467,491 | 5,953,171 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 698 | 521 | 912 | 3,327 | 8,481 | 13,939 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 14,560 | 10,010 | 17,160 | 41,730 | ||
| 11 | Total support. Add lines 7 through 10 | 6,008,840 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| PART II, LINE 10 | GROSS GOLF EVENT PROCEEDS 41,730 |
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990 - ORGANIZATION'S MISSION | ICAN'S MISSION IS TWO-FOLD: TO OPTIMIZE STAGE IV CANCER PATIENT SURVIVAL AND WORK TO ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. ICAN ASSISTS STAGE IV CANCER PATIENTS WITH 1) DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES; 2) REFERRALS TO ONCOLOGISTS IN ACADEMIC MEDICAL CENTERS AS WELL AS COMMUNITY PRACTICES; 3) EDUCATING PATIENTS REGARDING THE IMPERATIVE OF MOLECULAR PROFILING; 4) EXPEDITING ACCESS TO MOLECULAR PROFILING; 5) EDUCATING PATIENTS AND THEIR CARE PARTNERS REGARDING CLINICAL TRIALS AND MOLECULAR MATCHING OF THE PATIENT TO CLINICAL TRIALS; AND 6) EXPEDITING PATIENT ACCESS TO COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-SOLID TUMOR, PAN-SARCOMA, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND GALVANIZING OUR COLLABORATORS TO ASSIST UNDER-RESOURCED PATIENT COMMUNITIES IN THE UNITED STATES AND ABROAD. ICAN ANNUALLY AWARDS RESEARCH GRANTS BASED ON SPECIAL EVENT PROCEEDS AND SPONTANEOUS MEMORIAL AND TRIBUTE DONATIONS SUPPORTING OUR INTERNATIONAL RESEARCH CONSORTIUM'S GOAL TO DEFEAT RARE CANCERS SUCH AS EGFR EXON 20, HER2 EXON 20, AND MET ALTERATIONS. ICAN'S OVERARCHING FOCUS IS OUR DETAIL-ORIENTED PATIENT PROGRAM SERVICES AND RESEARCH ADVOCACY SERVICES WORKING CLOSELY WITH PATIENTS, CARE PARTNERS, CLINICIANS, SCIENTISTS, AND INVESTIGATORS WHO SHARE OUR RESEARCH GOALS. SEE ASKICAN.ORG AND UNDER THE ICAN NONPROFIT UMBRELLA: EXON20GROUP.ORG, BIOMARKERCOLLABORATIVE.ORG, METCRUSADERS.ORG, AND PDL1AMPLIFIEDS.ORG. |
| FORM 990, PAGE 2, PART III, LINE 4A | PATIENT NAVIGATION PROGRAMS, INCLUDING PATIENT PROGRAM SERVICES/RESEARCH ADVOCACY PROGRAMS/CANCER RESEARCH SERVICES OF WHICH 300,000 WAS AWARDED IN GRANTS TO INVESTIGATORS ASSOCIATED WITH OR COLLABORATING WITH ICAN'S INTERNATIONAL RESEARCH CONSORTIUM, INCLUDING THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS SOUTHWESTERN, THE UNIVERSITY OF PENNSYLVANIA, THE UNIVERSITY OF PITTSBURGH, AND THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. GRANTS WERE AWARDED FOR PROPOSALS RELATING TO MOLECULAR ALTERATIONS AND RESISTANCE MECHANISMS, DEVELOPMENT OF DRUGS WITH NEW MECHANISMS OF ACTION, DEVELOPMENT OF EARLY DETECTION ASSAYS, AND RESEARCH REGARDING LEPTOMENINGEAL DISEASE (LMD). THE 2023-2024 GRANT CYCLE WAS FUNDED BY ICAN'S SPECIAL EVENTS, INCLUDING THE ANNUAL FISTBUMP FUNDRAISER AND THE ANNUAL APPLIED UNDERWRITING GOLF TOURNAMENT AS WELL AS BY ICAN MEMORIAL AND TRIBUTE PROGRAMS. ICAN'S EXON 20 INTERNATIONAL RESEARCH CONSORTIUM CONSISTS OF TOP THORACIC RESEARCH ONCOLOGISTS AND SCIENTISTS WHO HAVE PRODUCED AN ARRAY OF TRANSFORMATIVE JOURNAL ARTICLES THAT ARE PROPELLING THE FIELD OF ACTIONABLE MUTATIONS FORWARD. ICAN'S PATIENT SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS. OUR PATIENTS, CARE PARTNERS, AND RESEARCH ADVOCATES REVIEW CLINICAL TRIAL CONCEPTS, PROTOCOLS, AND INFORMED CONSENT FORMS. THE ORGANIZATION'S ONCOLOGY NURSING SERVICES AND ANGEL BUDDIES/MET MENTORS (PEER-TO-PEER PATIENT AND CARE PARTNER ADVISORS) ASSIST PATIENTS AND THEIR FAMILIES WITH SIDE EFFECTS MITIGATION STRATEGIES THROUGHOUT CLINICAL TRIALS AND STANDARD TREATMENT. UNDER THE ICAN NONPROFIT UMBRELLA, ICAN MANAGES THE EXON 20 GROUP (EGFR EXON 20 WARRIORS/HER2 WARRIORS), THE MET CRUSADERS, THE BIOMARKER COLLABORATIVE, AND THE PD-L1 AMPLIFIEDS. |
| FORM 990, PAGE 2, PART III, LINE 4B | PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL ACCESS ISSUES RELATED TO UNDER- RESOURCED PATIENT COMMUNITIES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS FOR EXON 20 GROUP, MET CRUSADERS, BIOMARKER COLLABORATIVE, AND PAN-TUMOR ICAN PROGRAMS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND ABROAD. ICAN'S PUBLIC POLICY ADVOCACY EFFORTS WERE VIGOROUSLY PURSUED AT THE STATE AND FEDERAL LEVELS, INCLUDING ISSUES SUCH AS THE INFLATION REDUCTION ACT AND FIXING THE SMALL MOLECULE PENALTY; WEIGHING IN ON PRESCRIPTION DRUG AFFORDABILITY BOARDS; SUPPORTING PBM REFORM; SUPPORTING 340B PROGRAM REFORM; ADVOCATING THE PRESERVATION OF THE BAYH-DOLE PROGRAM; SUPPORTING BIOMARKER TESTING BILLS (PASSED IN 20 STATES AND COUNTING); SUPPORTING CO- PAY ACCUMULATOR AND REBATE REFORM BILLS (ACTIVE PARTICIPANT IN THE "ALL COPAYS COUNT COALITION"), AND OPPOSING STATE-LED EFFORTS THAT IMPEDE PATIENT ACCESS TO NOVEL THERAPEUTICS, SUCH AS STEP THERAPY/FAIL-FIRST THERAPY WHERE WE HAVE VIGOROUSLY OPPOSED THOSE ANTI-PATIENT PRACTICES SINCE 2012. |
| FORM 990, PAGE 2, PART III, LINE 4C | MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES: 1) ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND EDUCATING THEM ABOUT THE ARRAY OF MOLECULAR PROFILING TECHNOLOGIES THAT CAN EITHER BE ACCESSED BY PATIENTS AND/OR RESEARCHERS--DNA, RNA, AND THUS MULTI-OMICS: GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, METHYLATION, IMMUNE CELL STUDIES, AND SO FORTH; 2) REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS; 3) CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED, WITH THE INPUT OF MEMBERS OF ICAN'S BIOMARKERS COUNCIL, PHYSICIANS COUNCIL, AND DRUG DEVELOPMENT COUNCIL; 4) EDUCATING PATIENTS ABOUT MOLECULAR TUMOR BOARDS (E.G. TARGET CANCER'S TRACK STUDY, ASCO TAPUR STUDY; ROCHE NAVIFY); AND, 5) CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN-TUMOR/PAN- HEME/PAN-RARE CANCER BASIS IF AN APPROPRIATE CLINICAL TRIAL IS A MOLECULAR MATCH. ICAN AND ITS SUPPORT GROUPS ARE ALSO ENGAGED IN THE AREAS OF DECENTRALIZING TRIALS; "JUST-IN-TIME" TRIALS; AND EXPEDITING THE TRANSFER OF PATIENTS FROM ONE CLINICAL TRIALS SITE (MID-REGIMEN) TO ANOTHER MORE CONVENIENT SITE (U.S. TO U.S. OR EU TO U.S.). ICAN, THE EXON 20 GROUP, AND THE MET CRUSADERS SPECIALIZE IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. THE BIOMARKER COLLABORATIVE 1) CONNECTS PATIENTS TO BOTH THE APPROPRIATE SPECIFIC BIOMARKER SUPPORT GROUP AND THE RELEVANT GENERAL ORGANIZATIONS THAT COVER THE PATIENT'S SPECIFIC CANCER TYPE; AND 2) EDUCATES PATIENTS ABOUT THEIR DRIVER MUTATION, AMPLIFICATION OR FUSION (IF IDENTIFIED BY THE RELEVANT LABORATORY'S REPORT) AS WELL AS THEIR GENE CO-ALTERATIONS. ICAN AND ITS SUPPORT ORGANIZATIONS EACH STRESS THE IMPORTANCE OF MULTI-STAKEHOLDER COLLABORATIONS WITH RESEARCH ADVOCATES, PATIENT ADVOCATES, COMMUNITY ADVOCATES, CLINICIANS, AND SCIENTISTS. |
| FORM 990, PAGE 6, PART VI, LINE 11B | A COPY OF FORM 990 IS PROVIDED TO BOARD MEMBERS FOR THEIR REVIEW BEFORE THE FORM 990 IS FILED. THE CHAIRMAN OF THE BOARD OF TRUSTEES AND THE CHAIRS OF THE GOVERNANCE AND COMPENSATION COMMITTEES REVIEW, WITH ICAN'S CEO, COMMENTS REGARDING DRAFTS OF THE FORM 990. INPUT IS OBTAINED FROM MEMBERS OF ICAN'S INTERNAL AUDIT COMMITTEE AND SPECIAL EVENTS COMMITTEES. AT THE DIRECTION AND APPROVAL OF THE FULL BOARD, A SUBGROUP OF THE ORGANIZATION'S EXECUTIVE OFFICERS THEN COMPLETES ITS FINAL REVIEW, AND THE FORM 990 IS FILED. |
| FORM 990, PAGE 6, PART VI, LINE 12C | BOARD MEMBERS ANNUALLY DISCLOSE IN WRITING ALL POTENTIAL OR ACTUAL CONFLICTS OF INTEREST TO THE BOARD GOVERNANCE COMMITTEE. |
| FORM 990, PAGE 6, PART VI, LINE 15A | SINCE 2003, THE ORGANIZATION HAS ANNUALLY REVIEWED THE CEO'S COMPENSATION, WITH AN ANALYSIS THAT INCLUDES COMPARISONS TO OTHER CANCER ORGANIZATION CHIEF EXECUTIVE OFFICERS' COMPENSATION AS WELL AS OTHER HEALTH CARE NONPROFIT ORGANIZATION CHIEF EXECUTIVE OFFICERS' SALARIES. SEVERAL YEARS AGO, THE ORGANIZATION BENEFITED FROM AN EXTERNAL ORGANIZATION'S ANALYSIS THAT IS DEVOTED ENTIRELY TO FOR-PROFIT AND NONPROFIT EXECUTIVES' COMPENSATION. THE PROCESS AT ICAN INVOLVES THE COMPENSATION COMMITTEE CHAIRMAN'S ANNUAL REVIEW OF THE CEO AND KEY STAFF'S COMPENSATION, ON BEHALF OF THE BOARD OF TRUSTEES, BASED ON INTERNAL AND EXTERNAL INPUTS AND REVIEWS AND THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF ANY SALARY INCREASE OR EMPLOYEE BENEFITS SUCH AS HEALTH INSURANCE AND OTHER INSURANCE. |
| FORM 990, PAGE 6, PART VI, LINE 15B | THE PROCESS AT ICAN INVOLVES THE COMPENSATION COMMITTEE CHAIRMAN'S ANNUAL REVIEW OF THE CEO AND KEY STAFF'S COMPENSATION, ON BEHALF OF THE BOARD OF TRUSTEES, BASED ON INTERNAL AND EXTERNAL INPUTS AND REVIEWS AND THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF ANY SALARY INCREASE OR EMPLOYEE BENEFITS SUCH AS HEALTH INSURANCE AND OTHER INSURANCE. |
| FORM 990, PAGE 6, PART VI, LINE 19 | THE ORGANIZATION'S WEBSITE HAS AN EXTENSIVE BOARD GOVERNANCE SECTION. THE ORGANIZATION'S FORM 990 AS WELL AS ALL BOARD GOVERNANCE DOCUMENTS, INCLUDING CONFLICT OF INTEREST POLICY, WHISTLEBLOWER POLICY, AND DOCUMENTS RETENTION POLICY, ARE AVAILABLE ON ICAN'S WEBSITE (COMPENDIUM OF BOARD POLICIES) AND AT AVAILABLE AT GUIDESTAR/CANDID AS WELL AS CHARITY NAVIGATOR. |
| FORM 990, PART IX, LINE 11G | PATIENT SERVICES 110,925 0 0 PATIENT ACCESS/HEALTH EQUITY 177,004 0 0 OUTSIDE SERVICES 2,242 200 0 TOTAL 290,171 200 0 |
| Software ID: | |
| Software Version: |